1-3 of 3
Carol Moreno
Close
Sort by
Journal Articles

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

Clinical Trials & Observations
Carol Moreno, Isabelle G. Solman, Constantine S. Tam, Andrew Grigg, Lydia Scarfò, Thomas J. Kipps, Srimathi Srinivasan, Raghuveer Singh Mali, Cathy Zhou, James P. Dean, Edith Szafer-Glusman, Michael Choi
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5294–5303.
https://doi.org/10.1182/bloodadvances.2023010236
Published: 2023
Includes: Supplemental data
Journal Articles

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3440–3450.
https://doi.org/10.1182/bloodadvances.2021006434
Published: 2022
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data